SavedAdd your journal

Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2022 / Cilt: 32 - Sayı: 1

Intracavitary Bacillus Calmette-Guérin Treatment for Bladder Cancer: Is it Protective Against COVID-19?

Mesane Kanserinde İntrakaviter Bacillus Calmette-Guérin Tedavisi: COVID-19’a Karşı Koruyucu mu?

Mehmet Zeynel KESKİN
Mert Hamza ÖZBİLEN
Kenan TEKER
Pages
147–150
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Statistical relationships between the groups were analyzed using the chi-square test.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate whether the intravesical Bacillus Calmette-Guérin (BCG) administered to non-muscle invasive bladder cancer (NMIBC) patients has a protective effect against Coronavirus disease-2019 (COVID-19).
📊
Key Findings & Data:The patients were divided into 2x2 groups based on the conditions of having received BCG treatment and having had a COVID-19 infection.
💡
Conclusion & Impact:Statistical relationships between the groups were analyzed using the chi-square test.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate whether the intravesical Bacillus Calmette-Guérin (BCG) administered to non-muscle invasive bladder cancer (NMIBC) patients has a protective effect against Coronavirus disease-2019 (COVID-19). Methods: Six hundred and ninety-nine patients with NMIBC were enrolled in the study. The patients were divided into 2x2 groups based on the conditions of having received BCG treatment and having had a COVID-19 infection. The normality of the distribution was analyzed using the Shapiro-Wilk test. Statistical relationships between the groups were analyzed using the chi-square test. P

Özet

Amaç: Kas invaziv olmayan mesane kanseri (KİOMK) hastalarına uygulanan intravezikal Bacillus Calmette-Guérin'in (BCG) Koronavirüs hastalığı-2019’a (COVID-19) karşı koruyucu etkisinin olup olmadığını araştırmaktır. Yöntem: KİOMK'li 699 hasta çalışmaya alındı. Hastalar BCG tedavisi alma ve COVID-19 enfeksiyonu geçirme durumlarına göre 2x2 gruba ayrıldı. Dağılımın normalliği Shapiro-Wilk testi kullanılarak analiz edildi. Gruplar arasındaki istatistiksel ilişkiler ki-kare testi kullanılarak analiz edildi. P

🔖

Cite This Article

KESKİN, M. Z., ÖZBİLEN, M. H., TEKER, K. (2022). Intracavitary Bacillus Calmette-Guérin Treatment for Bladder Cancer: Is it Protective Against COVID-19?. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 32 - Sayı: 1, 147–150. https://ajindex.com/articles/558027

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157-60
  2. Türken M, Köse Ş. Covid-19 bulaş yolları ve önleme. J Tepecik Educ Res Hosp 2020;30:36-42
  3. Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work. Nat Med 2020. Online ahead of print 4. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324:460-70
  4. Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial threemonth experience. MedRxiv 2020
  5. Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet 2020;395:1545-6
  6. Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol 2020;17:316-7
  7. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011;8:e1001012
  8. Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011;204:245-52
  9. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A 2020;117:17720-6
  10. Peeples L. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci U S A 2020;117:8218-21
  11. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8:46-7
  12. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 2021;397:72-4
  13. Sharma A, Sharma SK, Shi Y, et al. BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic? Cell Death Dis 2020;11:516
  14. Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect 2019;25:1473-8
  15. Wardhana, Datau EA, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones 2011;43:185- 90
  16. Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis infection with H4: IC31 vaccine or BCG revaccination. N Engl J Med 2018; 379:138-49
  17. Arts RJW,